Betamethasone and Complications of Lower Third Molar Surgery

December 19, 2025 updated by: Shehab Ahmed Hamad

Effect of Betamethasone Injection Into the Pterygomandibular Space on Postoperative Sequelae of Impacted Lower Third Molar Surgery: A Randomized, Double-blind, Placebo-controlled Clinical Trial With a Split-mouth Design

Pain, swelling, and trismus are common sequalae of surgical removal of impacted third molars. The aim of this study is to evaluate effect of local administration of betamethasone, into the pterygomandibular space, on these sequalae

Study Overview

Detailed Description

A prospective, single center, double-blind, randomized controlled design study was conducted between January 2022 and February 2023, in the department of oral and maxillofacial surgery, Rizgary teaching hospital, Erbil, Iraq. The participants were patients presented for the surgical removal of bilateral symmetrical impacted lower third molars. To achieve 95% power, a sample size of 40 patients with bilateral impacted third molars was required.

The study was approved by the Ethical Committee of the institutional board and was conducted in accordance with the guidelines of the World Medical Association Declaration of Helsinki (1964) and its seventh amendment (2013) and to the Consolidated Standards of Reporting Trials (CONSORT) (Figurec1). The objectives of the study, as well as the risks and benefits were explained to the patients and those who agreed to participate have signed a consent form.

The inclusion criteria of the study were: individuals of both genders aging between 18 and 35 years, classified as ASA I according to the American Society of Anesthesiologists, and who have symmetrical bilateral impacted mandibular third molar detected by a panoramic radiograph. Impacted teeth categorized as mesiaoangular (Winter classification) and class II position B (Pell and Gregory classification) were included. The patients had no infection, pain, trismus, and swelling at the time of surgery.

Patients who are smokers, with pericoronitis, active infection, systemic disorders, on long term steroids, pregnant and lactating women were excluded. Patients were also precluded if they had taken analgesics 24 hours before- and antibiotics one week before the surgery, and if the surgical procedure exceeded 30 minutes or if more than three cartridges of local anaesthesia were used during the procedure.

By implementing the split mouth model, each participant underwent two surgical procedures, with an interval of at least 4 weeks between them. Prior to the first procedure, randomization of the first side to be operated (right or left) was performed using the "heads or tails" technique using a coin, where the head represented the right side and tails the left side.

The study group (group I) received 1 ml (6 mg) of betamethasone (CKOÇAK FARMA, Turkey) injection to the pterygomandibular space. Each ml contains 3.0 mg betamethasone acetate and 3.0 mg betamethasone sodium phosphate. The control group (group II) received a corresponding volume of normal saline injected into the pterygomandibular space. To ensure blinding of the study, the solution was injected by a third person, who is not directly involved in the surgery nor in the postoperative visits.

Impacted mandibular third molar surgery was performed under local anesthesia, using 2% lidocaine hydrochloride with 1:80,000 concentration of adrenaline. Inferior alveolar nerve, lingual and buccal nerve block technique were performed. After profound anesthesia was achieved, the betamethasone, or the sham solution, was injected into the pterygomandibular space using 3 ml disposable plastic syringe and gauge 25 hypodermic needle. A standard Ward's incision was designed and the mucoperiosteal fap was reflected to expose the surgical site. A lingual flap was reflected, only when deemed to be necessary. Bone guttering was made using round No.8 and straight fissure carbide bur (no. 703) bur, under copious saline irrigation. The tooth was sectioned or removed as whole. It was then luxated and delivered using elevators and forceps. The socket was thoroughly irrigated with normal saline solution done, after the rough bone margins were trimmed and finally the wound was closed with 3-0 Vicryl suture. The duration of surgery was measured from the time of incision to placement of the last suture.

The patient was given the usual postoperative instructions, including ice pack application to the operated side for 20 minutes, with 20-minute intervals between applications, for the first day. The patient was advised to consume cold liquid diet in the first day, and soft diet for the next 5 days. In addition, twice daily mouth wash with chlorhexidine 0.12% for 5 days, starting the day after surgery. Patients were given three days course of broad-spectrum antibiotic (amoxicillin 500 mg every eight hours or clindamycin 300 mg every eight hours if a penicillin allergy existed) and paracetamol 1g as a rescue analgesic.

The Facial swelling and the degree of trismus was recorded by the same operator, preoperatively and on the first, third, and seventh postoperative days. The pain was recorded by the patient, at 8:00 am, using visual analogue scale (VAS) at 1-5 postoperative days. . The patients rated pain on a 10-cm VAS, from no pain (0) to the most severe pain (10). Number of analgesic tablets consumed by the patients ,during the first five postoperative days, was also calculated. Flexible tape was used for measuring the following facial distances: gonion-lip commissure, gonion-external canthus of the eye, tragus-lip commissure, tragus-soft tissue pogonion. The sum of the preoperative measurements was considered as a baseline for the side of the face being assessed. Subtracting the preoperative measurement from the postoperative one indicated the amount of facial swelling. The degree of trismus was assessed by measuring the distance between the incisal edges of the upper and lower central incisors, on maximum mouth opening, using a digital vernier Statistical analyses was performed using the statistical package SPSS software 25.0. Comparisons between the groups was carried out using an independent t test. The significance level was set at P < 0.05.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Erbil, Iraq, 00441
        • Shehab Ahmed Hamad

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • healthy
  • no infection
  • no pain
  • no limitation of mouth opening
  • symmetrical bilateral impacted third molars (Mesioangular, CLASS II, Position B

Exclusion Criteria:

  • Infection
  • systemic disease
  • smokers
  • operation time exceeding 30 minutes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: betamethasone treated side
Betamethasone was administered into the pterygomandibular space immediately before surgery
The study group (group I) received 1 ml (6 mg) of betamethasone (CKOÇAK FARMA, Turkey) injection to the pterygomandibular space. Each ml contains 3.0 mg betamethasone acetate and 3.0 mg betamethasone sodium phosphate
Other Names:
  • Betamethasone injection ino the pterygomandibular space
Placebo Comparator: Control side
normal saline was administered into the pterygomandibular space immediately before surgery
normal saline

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative pain was assessed by patient self-report using a visual analogue scale (VAS; 0-10), where 0 indicated no pain and 10 indicated the worst imaginable pain.
Time Frame: Pain scores were recorded immediately after surgery and daily for the first five days
postoperative pain assessed by the patient on VAS pain score
Pain scores were recorded immediately after surgery and daily for the first five days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
trismus
Time Frame: Trismus was measured on the first, third, and seventh postoperative days
degree of maximum mouth opening measured between the maxillary and mandibular central incisors using a digital vernier
Trismus was measured on the first, third, and seventh postoperative days
Facial swelling
Time Frame: Facial swelling was measured on the first, third, and seventh postoperative days
Flexible tape was used for measuring the following facial distances: gonion-lip commissure, gonion-external canthus of the eye, tragus-lip commissure, tragus-soft tissue pogonion. The sum of the preoperative measurements was considered as a baseline for the side of the face being assessed. Subtracting the preoperative measurement from the postoperative one indicated the amount of facial swelling.
Facial swelling was measured on the first, third, and seventh postoperative days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Shehab Hamad, FFDRCSI, Kurdistan Higher Council of Medical Specialties

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 3, 2022

Primary Completion (Actual)

February 21, 2023

Study Completion (Actual)

March 26, 2023

Study Registration Dates

First Submitted

April 19, 2023

First Submitted That Met QC Criteria

December 19, 2025

First Posted (Actual)

December 22, 2025

Study Record Updates

Last Update Posted (Actual)

December 22, 2025

Last Update Submitted That Met QC Criteria

December 19, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Morbidity

Clinical Trials on normal saline

Subscribe